RxDoctor Payments DataLook up a doctor →

Safwan Kassas, MD

Interventional Cardiology · Saginaw, MINPI 1467432500

Payments from drug & device makers

$552,283in general payments, 2019–2025

Across 588 payments — averaging $939.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$499K
  • Boston Scientific$51K
  • Abbott$1K
  • Biocardia, Inc.$292
  • Novartis$286
  • Medtronic$215
  • plus $710 from 16 others

What the payments were for

  • Consulting fees$185,86955%
  • Speaking & faculty fees$69,91321%
  • Travel & lodging$75,10222%
  • Food & beverage$9,1363%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$552,283 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$160,028
Medicare patients
516
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$390,147
EntrestoSacubitril/Valsartan164$199,268
Repatha SureclickEvolocumab49$49,514
JardianceEmpagliflozin31$37,893
XareltoRivaroxaban20$28,982
NexlizetBempedoic Acid/Ezetimibe25$26,553
MultaqDronedarone Hcl12$26,552
Varenicline Tartrate59$18,475
Praluent PenAlirocumab36$18,067
BrilintaTicagrelor12$10,616
Metoprolol Succinate419$6,895
Atorvastatin Calcium316$5,598
Ranolazine ErRanolazine30$5,446
Ezetimibe90$4,168
Potassium Chloride143$3,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$390,147296 claims
NovartisEntresto$286$199,268164 claims
Boehringer IngelheimJardiance$27$37,89331 claims
Sanofi-aventis U.S. LLCMultaq$14$26,55212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →